News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Derma Sciences, Inc. (DSCI) Enters The Skin Substitute Market With Licensing Agreement For Innovative Amniotic Membrane Wound Care Products


1/14/2014 9:42:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces it has licensed exclusive rights to two novel human placental-derived tissue products for all dermal indications in the advanced wound care and burn markets from BioD LLC, a privately held company based in Memphis, Tenn. These products will be branded as AmnioMatrix® and launched during the third quarter of 2014, expanding Derma Sciences’ portfolio of advanced wound care (AWC) products into the $500 million skin substitute market. Terms of the license include an upfront cash payment, royalties on product sales and performance-based milestones to be paid in cash and Derma Sciences stock options.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES